PMID: 11607039Oct 19, 2001Paper

Ibudilast: a non-selective PDE inhibitor with multiple actions on blood cells and the vascular wall

Cardiovascular Drug Reviews
Y KishiM Isobe

Abstract

Ibudilast (3-isobutyryl-2-isopropylpyrazolo[1,5-a]pyridine) is a nonselective inhibitor of cyclic nucleotide phosphodiesterase (PDE). It is widely used in Japan for improving prognosis and relieving symptoms in patients suffering from ischemic stroke or bronchial asthma. These clinical applications are based on the properties of ibudilast that inhibit platelet aggregation, improve cerebral blood flow and attenuate allergic reactions. The inhibition of platelet aggregation and vasodilatation by ibudilast may be due to synergistic elevation of intracellular cyclic nucleotides and release of nitric oxide (NO) or prostacyclin from endothelium, rather than direct inhibition of PDE5 or PDE3. Another important property of ibudilast is its antiinflammatory activity possibly associated with potent inhibition of PDE4. Combined with its relaxing effects on bronchial smooth muscle, antiinflammatory activity of ibudilast could favorably influence pathophysiology of asthma by antagonizing chemical mediators triggering asthmatic attacks. Ibudilast was also reported to significantly attenuate inflammatory cell infiltration in the lumbar spinal cord in an animal model of encephalomyelitis. Future investigations should include effects of ibudila...Continue Reading

References

Jan 1, 1992·The Journal of Asthma : Official Journal of the Association for the Care of Asthma·A KawasakiS Yano
Nov 1, 1987·Naunyn-Schmiedeberg's Archives of Pharmacology·R BusseE Bassenge
Jun 1, 1993·Neurological Research·H FukuyamaJ Konishi
Aug 1, 1993·The American Review of Respiratory Disease·M IchinoseK Shirato
Feb 1, 1993·Japanese Journal of Pharmacology·K UmemuraM Nakashima
Oct 1, 1995·Journal of Cardiovascular Pharmacology·Y KishiF Numano
Jun 1, 1996·Stroke; a Journal of Cerebral Circulation·H NishimuraM Sugita
Dec 22, 1998·Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology·J ChiharaT Yamamoto
Jan 14, 1999·The New England Journal of Medicine·R Ross
Jul 13, 2000·Journal of Cardiovascular Pharmacology·Y KishiF Numano

❮ Previous
Next ❯

Citations

Apr 23, 2005·The American Journal of Chinese Medicine·Fong-Chi ChengGeorge G Yarbrough
Oct 9, 2004·Multiple Sclerosis : Clinical and Laboratory Research·Juan FengYasuto Itoyama
Nov 21, 2009·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·L M SanftnerK W Johnson
Jun 28, 2007·Expert Opinion on Investigational Drugs·Annemarie LedeboerKirk W Johnson
Jan 7, 2011·Expert Opinion on Therapeutic Targets·Federica Borghese, Felix I L Clanchy
Dec 7, 2013·Endocrine Reviews·Monalisa F AzevedoConstantine A Stratakis
Aug 2, 2007·Journal of Pharmacological Sciences·Takeharu KanedaKazumasa Shimizu
Feb 24, 2016·Future Medicinal Chemistry·Frédéric Bihel
Sep 22, 2015·Frontiers in Oncology·Michael D DeelCorinne M Linardic
Aug 9, 2016·Expert Opinion on Investigational Drugs·Andrew D GoodmanAndrew D Smith
Dec 3, 2016·Journal of Veterinary Pharmacology and Therapeutics·B T Simon, P V Steagall

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allergies & Environmental Factors

Environmental factors are strongly associated with the prevalence of allergies and are an increasing health concern worldwide. Discover the latest research on Allergies and Environmental Factors here.

Asthma

This feed focuses in Asthma in which your airways narrow and swell. This can make breathing difficult and trigger coughing, wheezing and shortness of breath.

Allergy and Asthma

Allergy and asthma are inflammatory disorders that are triggered by the activation of an allergen-specific regulatory t cell. These t cells become activated when allergens are recognized by allergen-presenting cells. Here is the latest research on allergy and asthma.